

Supplementary material

Supplementary table 1: Association between clinical or laboratory factors with echocardiographic parameters at the time of the first echocardiography (multivariable analysis with echocardiographic parameter as the endpoint) using an additional adjustment on atrial fibrillation (AF) status

LAVI determinants		
	exp (Beta)* ± SD	P
Pre-KT hypertension	1.312 ± 1.122	0.025
Valvular heart disease	1.574 ± 1.129	0.0007
Causal nephropathy		
Glomerulonephritis	1.007 ± 1.142	0.06
IgA nephropathy	0.786 ± 1.138	
Nephroangiosclerosis	0.787 ± 1.172	
Polycystic disease	1.042 ± 1.167	
Other	1.059 ± 1.162	
Malformative uropathy (ref)		
AVF closing	0.868 ± 1.089	0.11
Pre-KT AF	1.016 ± 1.176	0.41
De novo AF	1.167 ± 1.122	
None (ref)		
LVEF determinants		
	Beta ± SE	P
Pre-KT diabetes	7.139 ± 3.244	0.031
Post-KT eGFR (ml/min/1.73m ²)	0.139 ± 0.054	0.012
Post-KT use of ACEi/ARB	4.801 ± 2.174	0.031
Pre KT AF	-0.531 ± 4.346	0.31
De novo AF	-5.225 ± 3.396	
None (ref)		

KT: kidney transplantation; AVF: arteriovenous fistula; AF: atrial fibrillation; LAVI: left atrial volume index(mL/m²); LVEF: left ventricular ejection fraction (%); eGFR: estimated glomerular filtration rate (ml/min/1.73m²); ACEi: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blocker.

*In light of the distribution of LAVI, LAVI was log-transformed. exp(Beta) coefficient is reported to express associations with LAVI (rather than its log). Importantly, exp(Beta) should be interpreted on a multiplicative scale: e.g., patients with a history of pre-KT hypertension have 33% higher (exp[B]=1.329) LAVI than patients without.

Supplementary table 2: Association between clinical or laboratory factors with changes in echocardiographic parameters between the first and second echocardiography during follow-up (Δ =TTE2 – TTE1)) using an additional adjustment on atrial fibrillation (AF) status

	Beta \pm SD	P
Determinants of change in LAVI (LAVI2- LAVI1)		
LAVI (mL/m ²) at the time of TTE1	-0.325 \pm 0.156	0.043
Male sex	7.868 \pm 2.931	0.010
Pre-KT hypertension	9.725 \pm 4.232	0.026
ECD * (LD as reference)	3.814 \pm 3.660	0.30
SCD * (LD as reference)	-5.657 \pm 4.109	0.17
Induction therapy with ATG (basiliximab as reference)	8.075 \pm 3.116	0.013
Pre KT AF De novo AF None (ref)	2.132 \pm 5.565 -0.688 \pm 4.559	0.90
Determinants of change in LVEF (LVEF2-LVEF1)		
4-cavity LVEF at the time of TTE1	-0.825 \pm 0.173	<0.0001
Haemoglobin at the time of TTE1 (g/dl) > median (>12.9g/dL)	6.027 \pm 3.034	0.052
ACEi/ARB	8.269 \pm 3.245	0.013
Pre KT AF De novo AF None (ref)	-0.108 \pm 6.153 0.538 \pm 5.557	0.99

* p for the difference between ECD and SCD =0.0064

LAVI: left atrial volume index; KT : kidney transplantation; ECD: expanded criteria donor; SCD: standard criteria donor; LD: living donor; ATG: anti-thymocyte globulin; AF : atrial fibrillation; LVEF: left ventricular filtration ejection; eGFR: estimated glomerular filtration rate; ACEi: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blocker